Precision Oncology & Companion Diagnostics: US FDA Approves Roche’s PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH Assays as First Companion Diagnostics for HER2-Positive Esophageal and Metastatic Gastroesophageal Adenocarcinoma (GEA) to Direct ZIIHERA® Therapy

Key Development

The U.S. Food and Drug Administration (FDA) has granted expanded approval for two companion diagnostic (CDx) assays developed by Roche Diagnostics (SIX: ROG): the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail assay.

The expanded indication validates both assays to assess human epidermal growth factor receptor 2 (HER2) status in patients diagnosed with metastatic gastroesophageal adenocarcinoma (GEA)—encompassing gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, and esophageal adenocarcinoma.

Clinical Pairing with Jazz Pharmaceuticals’ Targeted Bispecific ZIIHERA®:

• Validated Companion Diagnostics for Targeted Selection: Roche’s assays are now the approved diagnostic tools to identify HER2-positive ($HER2+$) GEA patients eligible for treatment with ZIIHERA® (zanidatamab-hrii), a targeted bispecific antibody commercialized by Jazz Pharmaceuticals.

• First-Line FDA Regimens: The FDA approved two ZIIHERA-containing systemic regimens for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive GEA.

• Historical Milestone in Esophageal Cancer Testing: Represents the first-ever FDA-approved companion diagnostic cleared to determine HER2 status specifically in esophageal adenocarcinoma, removing a major diagnostic barrier that previously restricted patient access to targeted biological therapies.

Why It Matters

• Expanding Therapeutic Avenues for Late-Stage Aggressive Malignancies: Gastroesophageal adenocarcinomas represent aggressive gastrointestinal tract cancers frequently diagnosed at advanced, unresectable, or metastatic stages. Historically associated with poor 5-year survival rates and cytotoxic treatment options, identifying HER2 overexpression allows oncologists to deploy bispecific targeted therapies to improve patient outcomes.

• Seamless Turnaround via Global Pathology Infrastructure: Both PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH tests are integrated on Roche’s automated BenchMark IHC/ISH staining instruments, which are installed across hospital and commercial pathology laboratories worldwide. The expanded label enables pathology labs to run GEA samples without capital investments or changes to existing workflows.

• Complementary Dual IHC & ISH Diagnostic Algorithm: Combining Immunohistochemistry (IHC—measuring HER2 membrane protein overexpression) with Dual In Situ Hybridization (ISH—quantifying HER2/CEP17 gene amplification ratios) resolves diagnostic ambiguity in gastroesophageal tumors known for high intratumoral heterogeneity.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the August 27, 2026 FDA approval of Roche Diagnostics’ expanded assays demonstrates Precision Oncology Drug-CDx Co-Evolution & Upper-GI Expansion.

This diagnostic clearance advances three precision oncology dynamics:

1. Unlocking Next-Generation Bispecific Biology (Zanidatamab): Zanidatamab engages two non-overlapping extracellular domains of HER2 (domain II and domain IV) simultaneously, inducing HER2 receptor clustering, rapid internalization, and enhanced antibody-dependent cellular cytotoxicity (ADCC). High-precision diagnostic screening is required to identify tumor populations with sufficient receptor density.

2. Standardizing Esophageal HER2 Profiling: Prior to this approval, the lack of a standardized, FDA-cleared HER2 assay for esophageal adenocarcinoma led to inconsistent off-label diagnostic practices. Establishing formal diagnostic criteria standardizes scoring protocols for pathologists.

3. Synergy Between Diagnostics Conglomerates and Targeted Biopharma: Reaffirms the dominant role of Roche Diagnostics in companion biomarker development. Biopharmaceutical innovators partner with Roche to leverage its global laboratory testing footprint, facilitating rapid commercial uptake of newly cleared precision oncology drugs.

Market Implications

1. Increased Consumable Volume for Roche Tissue Diagnostics: Drives sustained utilization of PATHWAY 4B5 antibody dispensers and VENTANA ISH probe cocktail kits across clinical pathology networks.

2. Accelerated U.S. Commercial Trajectory for ZIIHERA® (Jazz Pharmaceuticals): Provides the validated diagnostic framework necessary for community and academic oncologists to initiate first-line ZIIHERA treatment regimens.

3. Guideline Harmonization Across CAP, ASCO, and NCCN: Professional pathology and clinical oncology bodies (including CAP, ASCO, and NCCN) will update clinical practice guidelines to mandate routine HER2 IHC/ISH reflex testing for all newly diagnosed metastatic esophageal adenocarcinoma cases.

Diagnostic Specification Matrix: Roche HER2 Assays for GEA

Parameter	Technical Specifications & Diagnostic Method	Strategic & Clinical Significance
Approved Assays	PATHWAY HER2 (4B5) & VENTANA HER2 Dual ISH	Standardized IHC protein and ISH gene assays.
Assay Developer	Roche Diagnostics (F. Hoffmann-La Roche Ltd)	Global market leader in automated tissue diagnostics.
Expanded Indication	Metastatic Gastroesophageal Adenocarcinoma (GEA)	Covers gastric, GE junction, and esophageal cancers.
Regulatory Precedent	First FDA-cleared HER2 test for esophageal cancer	Establishes standardized HER2 diagnostic scoring.
Paired Therapeutic	ZIIHERA® (zanidatamab-hrii) (Jazz Pharma)	Indicated for first-line treatment of HER2+ metastatic GEA.
Automated Platform	BenchMark series automated slide stainers	Utilizes existing global pathology laboratory networks.

Source: https://vohnetwork.com/news/precision-medicine/roche-receives-fda-approval-for-her2-companion-diagnostics-in-metastatic-gea